Joseph F. Goldberg, MD Clinical Professor of Psychiatry Icahn School of Medicine at Mount Sinai New York, New York Director, Affective Disorders Research Program Silver Hill Hospital New Canaan, Connecticut
Disclosure Dr. Goldberg has been a consultant to Avanir Pharmaceuticals and Merck; has served on the speakers’ bureau for AstraZeneca, Merck, Novartis, Sunovion Pharmaceuticals, and Takeda and Lundbeck; and has received royalties from American Psychiatric Publishing and honoraria from Medscape and WebMD.
Editor’s note: The second part of Dr. Goldberg’s review of depression subtypes—focusing on “situational,” treatment-resistant, melancholic, agitated, anxious, and atypical depression; depression occurring with a substance use disorder; premenstrual dysphoric disorder; and seasonal affective disorder—will appear in the May 2014 issue of Current Psychiatry.
